Followers | 371 |
Posts | 5333 |
Boards Moderated | 1 |
Alias Born | 05/09/2013 |
Friday, August 12, 2016 3:36:17 PM
Since it pulled back and held 1.50+, it's been rewarding for those who've still held.
I'm not sure if I will buy it or chase it above 1.60's, but it would not surprise me to see it one day explode on data news) or at least go back to 1.80-1.90-2.00 just based on its tight float.
But earnings on these type of stocks is always a coin toss, so be aware of that risk.
I favor ORPN above most for chance of good earnings, but realize (as a good standard rule to trade by), it is a 'coin toss' and a high risk in general to hold before earnings.
But also possible they update good news on earnings, too, so anything is possible.
--------------------------------------------------------------------------------------------------------------
That said, I have an arsenal of numerous alternative ideas (mostly biotechs, along with re-entry into LABD later on) which I'm looking at going into at anytime, so I'm not worried about missing any new bounce back up on ORPN.
I never trade desperate (and don't worry about chasing a gap up), as I always or usually can find another good opportunity at any given time typically.
Recent ENLV News
- Enlivex CEO Issues Letter to Shareholders – Perspectives on Recent Events • GlobeNewswire Inc. • 04/29/2024 12:00:00 PM
- Enlivex Announces Dosing of First Two Patients in its Randomized, Controlled Phase I/II Trial Evaluating Allocetra™ in Patients with Knee Osteoarthritis • GlobeNewswire Inc. • 04/22/2024 12:00:00 PM
- Yet Another Biotech Stock Has Found Success During Tuesday's Session • AllPennyStocks.com • 04/16/2024 08:55:00 PM
- Enlivex Announces Authorization from the Danish Regulatory Agency for the Company’s Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis • GlobeNewswire Inc. • 04/16/2024 11:50:00 AM
- Enlivex to Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra™ In Patients with Sepsis • GlobeNewswire Inc. • 04/11/2024 06:58:20 PM
- Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis • GlobeNewswire Inc. • 04/11/2024 12:05:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/07/2024 01:02:02 PM
- Enlivex Announces Issuance of New U.S. Patent Covering Allocetra Cells and Their Manufacturing Method • GlobeNewswire Inc. • 02/07/2024 01:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/22/2024 01:00:17 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/17/2024 01:02:25 PM
- Enlivex Receives IMOH Regulatory Authorization for the Initiation of a Multi-Country, Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Up To 160 Patients with Moderate to Severe Knee Osteoarthritis • GlobeNewswire Inc. • 01/17/2024 01:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/20/2023 01:01:21 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/09/2023 09:30:07 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/07/2023 09:30:02 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/02/2023 08:30:03 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 10/26/2023 08:30:52 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/18/2023 12:00:27 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/13/2023 08:42:24 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/11/2023 12:00:04 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/01/2023 08:30:27 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/02/2023 12:05:26 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/31/2023 12:05:23 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM